NCT07475806 2026-03-17
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Astellas Pharma Inc
Phase 2 Not yet recruiting
Clinical Trials
19 trialsNCT07469774 2026-03-13
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07452224 2026-03-12
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
iLeukon Therapeutics, Inc.
Phase 2 Not yet recruiting
NCT07431827 2026-02-25
KANDLELIT-013
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT07361510 2026-02-19
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Bristol-Myers Squibb
Phase 3 Not yet recruiting
NCT07415031 2026-02-17
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Not yet recruiting
NCT07365319 2026-01-26
TeLuRide-008
Eikon Therapeutics
Phase 2/3 Not yet recruiting
NCT07318883 2026-01-06
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
NCT06093425 2025-12-17
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 3 Not yet recruiting
NCT06724042 2025-12-10
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Not yet recruiting
NCT05077215 2025-12-08
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Evergreen Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT05106127 2025-12-08
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
Evergreen Therapeutics, Inc.
Phase 2 Not yet recruiting
NCT06400160 2025-11-25
Clinical Trial of TB511 in Advanced Solid Tumors
Twinpig Biolab, Inc.
Phase 1/2 Not yet recruiting
NCT07244393 2025-11-24
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Cellbion Co., Ltd.
Phase 1 Not yet recruiting
NCT07162883 2025-09-09
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT04901741 2025-06-27
OPTIMUS
TME Pharma AG
Phase 2 Not yet recruiting
NCT06868732 2025-03-11
Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Not yet recruiting
NCT05425576 2024-03-15
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Mateon Therapeutics
Phase 2 Not yet recruiting
NCT05366062 2022-05-13
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
Epitopoietic Research Corporation
Phase 2 Not yet recruiting